ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of “Hold” from Analysts

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) have received an average rating of “Hold” from the five analysts that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $30.6667.

A number of equities analysts have commented on the stock. Roth Mkm started coverage on shares of ARS Pharmaceuticals in a research report on Tuesday, November 4th. They set a “buy” rating and a $30.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Zacks Research downgraded shares of ARS Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 27th.

Institutional Investors Weigh In On ARS Pharmaceuticals

Large investors have recently bought and sold shares of the company. CWM LLC boosted its position in shares of ARS Pharmaceuticals by 243.7% during the 3rd quarter. CWM LLC now owns 2,547 shares of the company’s stock worth $26,000 after acquiring an additional 1,806 shares in the last quarter. Torren Management LLC bought a new stake in ARS Pharmaceuticals during the fourth quarter worth $32,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of ARS Pharmaceuticals by 25.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company’s stock valued at $56,000 after purchasing an additional 982 shares in the last quarter. Osterweis Capital Management Inc. bought a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at $65,000. Finally, Russell Investments Group Ltd. increased its stake in shares of ARS Pharmaceuticals by 197.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,668 shares of the company’s stock valued at $67,000 after purchasing an additional 4,427 shares during the last quarter. 68.16% of the stock is currently owned by institutional investors and hedge funds.

ARS Pharmaceuticals Trading Down 4.7%

Shares of NASDAQ:SPRY opened at $9.00 on Friday. ARS Pharmaceuticals has a 52-week low of $6.66 and a 52-week high of $18.90. The company has a debt-to-equity ratio of 1.14, a quick ratio of 6.51 and a current ratio of 6.66. The company has a market capitalization of $889.65 million, a P/E ratio of -11.11 and a beta of 0.79. The company has a 50-day simple moving average of $10.53 and a 200 day simple moving average of $10.66.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.